ArticleInternational journal of nanomedicine2013
Local delivery of controlled-release simvastatin/PLGA/HAp microspheres enhances bone repair.
Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 94 citations in OpenAlex.
- Tomographic evaluation of the effect of simvastatin topical use on alveolar bone microarchitecture, pain and swelling after mandibular third molar extraction: a randomized controlled trial.Clinical oral investigations · 2022Trial
- Poly(Lactic-Co-Glycolic Acid)-Based Systems in Implantology: Advances in Biomaterial Design, Drug Delivery, and Tissue Regeneration.Polymers · 2026Review
- Prospective and challenges of locally applied repurposed pharmaceuticals for periodontal tissue regeneration.Frontiers in bioengineering and biotechnology · 2024Review
- Recent progress in the manipulation of biochemical and biophysical cues for engineering functional tissues.Bioengineering & translational medicine · 2023Review
- Bone-Targeting Nanoparticles of a Dendritic (Aspartic acid)International journal of molecular sciences · 2022Article
- Article
- Article
- Fabrication of Silk Scaffold Containing Simvastatin-Loaded Silk Fibroin Nanoparticles for Regenerating Bone DefectsIranian biomedical journal · 2022Article
- Sustained release of naringin from silk-fibroin-nanohydroxyapatite scaffold for the enhancement of bone regeneration.Materials today. Bio · 2022Article
- Poly(lactic-Bioactive materials · 2021Review
- Polymer Scaffolds-Enhanced Bone Regeneration in Osteonecrosis Therapy.Frontiers in bioengineering and biotechnology · 2021Review
- Engineered three-dimensional scaffolds for enhanced bone regeneration in osteonecrosis.Bioactive materials · 2020Article
- Modified electrospun chitosan membranes for controlled release of simvastatin.International journal of pharmaceutics · 2020Article
- Adjuvant Drug-Assisted Bone Healing: Advances and Challenges in Drug Delivery Approaches.Pharmaceutics · 2020Review
- Article
- 20(S)-hydroxycholesterol and simvastatin synergistically enhance osteogenic differentiation of marrow stromal cells and bone regeneration by initiation of Raf/MEK/ERK signaling.Journal of materials science. Materials in medicine · 2019Article
- Mimicking growth factors: role of small molecule scaffold additives in promoting tissue regeneration and repair.RSC advances · 2019Review
- In vitro and in vivo evaluation of chitosan scaffolds combined with simvastatin-loaded nanoparticles for guided bone regeneration.Journal of materials science. Materials in medicine · 2019Article
- Combination of a Bioceramic Scaffold and Simvastatin Nanoparticles as a Synthetic Alternative to Autologous Bone Grafting.International journal of molecular sciences · 2018Article
- Scaffolds as Structural Tools for Bone-Targeted Drug Delivery.Pharmaceutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins are used clinically for reduction of cholesterol synthesis to prevent cardiovascular disease. Previous in vitro and in vivo studies have shown that statins stimulate bone formation. However, orally administered statins may be degraded during first-pass metabolism in the liver. This study aimed to prevent this degradation by developing a locally administered formulation of simvastatin that is encapsulated in poly(lactic-co-glycolic acid)/hydroxyapatite (SIM/PLGA/HAp) microspheres with controlled-release properties. The effect of this formulation of simvastatin on bone repair was tested using a mouse model of gap fracture bridging with a graft of necrotic bone. The simvastatin released over 12 days from 3 mg and 5 mg of SIM/PLGA/HAp was 0.03-1.6 μg/day and 0.05-2.6 μg/day, respectively. SIM/PLGA/HAp significantly stimulated callus formation around the repaired area and increased neovascularization and cell ingrowth in the grafted necrotic bone at week 2 after surgery. At week 4, both 3 mg and 5 mg of SIM/PLGA/HAp increased neovascularization, but only 5 mg SIM/PLGA/HAp enhanced cell ingrowth into the necrotic bone. The low dose of simvastatin released from SIM/PLGA/HAp enhanced initial callus formation, neovascularization, and cell ingrowth in the grafted bone, indicating that SIM/PLGA/HAp facilitates bone regeneration. We suggest that SIM/PLGA/HAp should be developed as an osteoinductive agent to treat osteonecrosis or in combination with an osteoconductive scaffold to treat severe bone defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.